CSIMarket
 
Kronos Bio Inc   (KRON)
Other Ticker:  
 
 
Price: $1.1600 $0.02 1.754%
Day's High: $1.22 Week Perf: -6.45 %
Day's Low: $ 1.08 30 Day Perf: 10.48 %
Volume (M): 280 52 Wk High: $ 2.29
Volume (M$): $ 324 52 Wk Avg: $1.37
Open: $1.12 52 Wk Low: $0.73



 Market Capitalization (Millions $) 67
 Shares Outstanding (Millions) 58
 Employees 57
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -119
 Cash Flow (TTM) (Millions $) -10
 Capital Exp. (TTM) (Millions $) 1

Kronos Bio Inc
Kronos Bio Inc is a US-based clinical-stage biopharmaceutical company that was founded in 201 The company is engaged in the research and development of small molecule drugs that can target historically difficult to drug protein targets. It aims to develop novel drug therapies for the treatment of various oncology and immunology diseases. The company is headquartered in New York City and has a team of dedicated scientists and professionals committed to discovering new therapeutics.

The companyes founders, Norbert Bischofberger and Angela Koehler, possess extensive experience in drug discovery and development, including serving as executives at Gilead Sciences, one of the largest biopharmaceutical companies in the world. Kronos Bio utilizes its proprietary chemistry technology, which combines innovative medicinal chemistry with modern computational biology, to discover and develop highly specific and efficient small molecule drugs against historically undruggable targets.

Kronos Bioes lead product candidate, entospletinib (formerly LSF-121), is a highly selective and potent inhibitor of spleen tyrosine kinase (SYK). This drug has been developed for the treatment of patients with acute myeloid leukemia (AML) and non-Hodgkines lymphoma (NHL). Currently, the company is conducting multiple clinical trials for entospletinib in patients with AML and NHL.

Aside from entospletinib, the company also has several other promising drug candidates in its pipeline. KB-0742 is a highly selective inhibitor of cyclin-dependent kinase 9 (CDK9), which is being developed for the treatment of various hematologic malignancies and solid tumors. KB-0742 has demonstrated higher specificity and potency than currently available CDK9 inhibitors, which could lead to fewer side effects and better clinical outcomes for patients.

Kronos Bio is committed to transforming the way we treat cancer and other devastating diseases. With its innovative approach to drug discovery and development, the company is uniquely positioned to develop highly targeted and effective drug therapies against historically undruggable targets. The company has received significant interest and funding from venture capitalists, including $105 million in a series A funding round in 2019. Overall, Kronos Bio has the potential to make a significant impact in the biopharmaceutical industry and improve patient outcomes.


   Company Address: 1300 So. El Camino Real San Mateo 94402 CA
   Company Phone Number: 781-5200   Stock Exchange / Ticker: NASDAQ KRON
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Kronos Bio's Restructuring Strategy and Ongoing Clinical Development of KB-0742

Published Thu, Mar 7 2024 9:05 PM UTC

In recent news, Kronos Bio, a clinical-stage biopharmaceutical company, has announced a strategic restructuring aimed at optimizing resources for its clinical development efforts. The company plans to focus primarily on advancing KB-0742, a promising investigational therapy, and extending its cash runway. This article aims to ly interpret the key facts from Kronos Bio's anno...

Clinical Study

Kronos Bio Steers Cancer Treatment into a New Frontier: Groundbreaking Advances Unveiled at AACR 2024 Annual Meeting

Published Tue, Mar 5 2024 9:44 PM UTC

Kronos Bio's Presentation at AACR 2024 Annual Meeting Highlights Cutting-Edge Advances in Cancer Research San Mateo, California and Cambridge, Massachusetts - Kronos Bio, Inc. (Nasdaq: KRON), a pioneering company committed to revolutionizing cancer treatment, has set the stage for a momentous breakthrough at the upcoming American Association for Cancer Research (AACR) annual...

Management Changes

Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement Amid Financial Challenges

Published Thu, Jan 25 2024 1:00 PM UTC



In a move to propel its pipeline advancement and streamline operations, Kronos Bio Inc has recently implemented a new leadership structure. This restructuring includes the elimination of three executive officer roles and the appointment of a new Executive Leadership team. However, these strategic changes come at a time when the company has recorded a significant ne...

Clinical Study

Kronos Bio's Breakthroughs and Challenges: Advancing Precision Oncology with Promising AML Research and Unexpected Hurdles

Published Mon, Dec 18 2023 9:07 PM UTC



In a recent pipeline update, Kronos Bio, a leading clinical-stage biopharmaceutical company, has made significant strides in their research and development efforts. While showcasing progress in their Phase 1b study for relapsed/refractory FLT3-mutated acute myeloid leukemia (AML), they also faced an unexpected hurdle in the advancement of their p300 KAT inhibitor ...

Kronos Bio Inc

Kronos Bio Inc Reveals Remarkable Resilience with $0.917 Million Revenue Amid Challenging Market Conditions



In the third quarter of 2023, Kronos Bio Inc, a major pharmaceutical preparations company, disclosed a revenue of $0.917 million. Despite a slight decrease in revenue compared to the previous year, the company demonstrated resilience in the face of challenging market conditions. Kronos Bio Inc also reported a net deficit of $-31.374 million in the same quarter, indicating a slight improvement from the previous year's deficit of $-32.256 million.
Looking ahead, the company is expected to report its next financial earnings on March 14, 2024. This announcement is eagerly awaited by investors, who will be monitoring the company's performance closely.






 

Kronos Bio Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com